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Bone tissue engineering requires an osteoconductive scaffold, multipotent cells with regenerative
capacity and bioactive molecules. In this study we investigated the osteogenic differentiation of human
adipose tissue-derived mesenchymal stem cells (hAD-MSCs) on titanium dioxide (TiO2) scaffold coated
with alginate hydrogel containing various concentrations of simvastatin (SIM). The mRNA expression
of osteoblast-related genes such as collagen type I alpha 1 (COL1A1), alkaline phosphatase (ALPL),
osteopontin (SPP1), osteocalcin (BGLAP) and vascular endothelial growth factor A (VEGFA) was enhanced
in hAD-MSCs cultured on scaffolds with SIM in comparison to scaffolds without SIM. Furthermore, the
secretion of osteoprotegerin (OPG), vascular endothelial growth factor A (VEGFA), osteopontin (OPN)
and osteocalcin (OC) to the cell culture medium was higher from hAD-MSCs cultured on scaffolds with
SIM compared to scaffolds without SIM. The TiO2 scaffold coated with alginate hydrogel containing
SIM promote osteogenic differentiation of hAD-MSCs in vitro, and demonstrate feasibility as scaffold
for hAD-MSC based bone tissue engineering.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The use of autologous stem cells has been exploited as a
strategy to facilitate healing of bone defects resulting from trauma,
disease, surgery or congenital malformations [1]. Among the differ-
ent cell-types investigated are stem cells from adipose tissue,
which appear to be a promising candidate for osseous reconstruc-
tion [2–4]. The abundant and easily available hAD-MSCs [5,6] can
undergo rapid and efﬁcient osteogenic differentiation in vitro [7].
However, undifferentiated hAD-MSCs do not undergo osteogenic
differentiation in vivowithout inductive stimuli [8,9]. Over the past
years SIM, widely used to treat hyperlipidemia and arteriosclerosis[10], has gained interest as an appealing candidate for bone tissue
engineering because of its osteogenetic properties [11]. Further-
more, SIM has been shown to induce osteogenic differentiation of
hAD-MSCs when cultured in a standard two-dimensional culture
environment [12]. However, for reconstruction of large-size bone
defects a three-dimensional scaffold is needed to support the
healing [13]. Several types of synthetic scaffolds have been tested
to provide the needed support, but scaffolds lacking osteoinductive
signals may not be effective in inducing bone regeneration
following hAD-MSC transplantation [14,15]. The scaffolds should
therefore be engineered to provide biochemical cues for promoting
stem cell-mediated osteogenesis as well as proper physical and
mechanical microenvironments. Modiﬁcation of scaffolds with
osteoinductive molecules can compensate for the lack of osteo-
genic properties. Recently, the development of porous and well
interconnected ceramic TiO2 scaffold coated with alginate hydrogel
containing SIM has been described [16]. The TiO2 scaffold has a
high mechanical strength [17] and has been reported as a candi-
date for use in large-size bone defects [18,19].
The aim of this study was to evaluate the cell viability and oste-
ogenic potential of hAD-MSCs seeded on TiO2 scaffold coated with
alginate hydrogel containing SIM.
Table 1
List of probes used in qRT-PCR.
Gene
symbol
Gene name TaqMan assay
No.
GAPDH Glyceraldehyde-3-phosphate
dehydrogenase
Hs99999905_m1
RUNX2 Runt-related transcription factor 2 Hs00231692_m1
SOX9 SRY (sex determining region Y)-box 9 Hs00165814_m1
PPARG Peroxisome proliferator-activated receptor
gamma
Hs01115513_m1
COL1A1 Collagen type I alpha 1 Hs00164004_m1
SPP1 Osteopontin Hs00959010_m1
TNFRSF11B Osteoprotegerin Hs00900360_m1
ALPL Alkaline phosphatase Hs00758162_m1
BGLAP Osteocalcin Hs01587814_g1
VEGFA Vascular endothelial growth factor A Hs00900055_m1
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2.1. Production of TiO2 scaffolds coated with alginate hydrogel
containing SIM
Porous TiO2 scaffolds, 8 mm in height and a diameter of 9 mm,
were produced as previously described [20]. The scaffolds were
subsequently sterilized by autoclaving.
SIM (Krebs Biochemicals & Industries, Andhra Pradesh, India)
was dissolved in 100% ethanol to 10 mM before being added to
2% (w/v) Pronova UP LVG sodium alginate (FMC BioPolymer,
Sandvika, Norway) in milliQ water at desired concentrations
(10 lM, 1 lM, 0.1 lM, and 10 nM) to create TiO2 scaffolds coated
with alginate hydrogel containing SIM as described previously
[16]. The scaffolds for the control group were coated with alginate
hydrogel without SIM.
2.2. Cell culture and seeding of hAD-MSCs
The hAD-MSCs were isolated from liposuction material from
abdominal regions of three healthy female donors (ages 36, 50,
61 years). The donors provided informed consent, and the collec-
tion and storage of adipose tissue and hAD-MSCs were approved
by the regional committee for ethics in medical research. The
isolation and in vitro expansion of hAD-MSCs were carried out as
previously described [21]. The hAD-MSCs were cultured in culture
medium consisting of Dulbecco’s modiﬁed Eagle’s medium/F12
(Gibco/BRL, Carlsbad, CA, USA) supplemented with 10% human
platelet lysate plasma, 1000 IU/ml heparin (Wockhardt, Wrexham,
UK) and 1% penicillin, streptomycin and amphotericin B. Cells were
subcultured at conﬂuence and expanded for 4–5 passages.
Cell seeding on alginate-coated scaffolds with or without SIM
was performed using an agitated seeding method in order to
ensure a homogenous cell distribution throughout the scaffolds
[22]. Scaffolds pre-soaked with culture medium were placed in
48-well plates, and 1 ml cell suspension was added drop-wise on
the top of the scaffolds at a density of 4  105 cells/ml. After
seeding, the plates were agitated on an orbital shaker at 200 rpm
for 6 h at 37 C. Following agitation the cell-seeded scaffolds were
transferred to new culture plates in 1 ml culture medium and
maintained at 37 C in a humidiﬁed atmosphere of 5% CO2 for up
to 21 days. Cells from one donor (in triplicate) were used for the
initial cytotoxicity study of SIM at different concentrations
(10 lM, 1 lM, 0.1 lM, and 10 nM). Cells from three individual
donors were used for all subsequent studies. Triplicates of each
donor, each treatment, and for three harvest time points were
included, giving a total of 54 scaffolds. The culture medium was
changed every second day and collected for analyses. Scaffolds
were harvested after 7, 14 and 21 days of culture for use in qRT-PCR.
2.3. Determination of LDH activity in culture medium
The culture medium was collected every second day up till
14 days, and the cytotoxic effect of SIM containing scaffolds was
evaluated based on the LDH activity. The LDH activity was
analyzed with a cytotoxicity detection kit (Roche Diagnostics,
Mannheim, Germany) according to themanufacturer’s instructions.
The absorbance was measured at 492 nm in a plate reader
(Biochrom Asys Expert 96 Microplate Reader, Biochrom, Holliston,
MA, USA).
2.4. RNA isolation and qRT-PCR analysis
Total RNA was isolated by the Qiagen RNA mini-kit (Qiagen,
Hilden, Germany) according to the protocol provided by themanufacturer. The cDNA was synthesized with RevertAid First
Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany)
using random primers. QRT-PCR was performed in the Applied
Biosystems 7300 Real-Time System (Life Technologies, Paisley,
UK) with TaqMan Universal PCR Master Mix and TaqMan Gene
Expression Assays (Applied Biosystems, Paisley, UK). QRT-PCR
was done for GAPDH, RUNX2, SOX9, PPARG, COL1A1, SPP1,
TNFRSF11B, ALPL, BGLAP and VEGFA. List of probes used in qRT-PCR
is provided in Table 1. QRT-PCR analysis was performed in
duplicate for SIM 10 nM and control groups at days 7, 14 and 21.
Relative mRNA levels were calculated by the comparative CT
method [23].
2.5. Quantiﬁcation of secreted proteins
Multianalyte proﬁling of protein levels in the culture medium
was performed on the Luminex 200 system (Luminex, Austin, TX,
USA) employing xMAP technology. Acquired ﬂuorescence data
was analyzed by the xPONENT 3.1 software (Luminex, Austin, TX,
USA). The amount of OPN, OPG, VEGFA and OC in the culture med-
ium after 2, 4, 8, 14 and 21 days incubation was measured using
the human bone panel and human cytokine/chemokine kits
(Millipore, Billerica, MA, USA). All analyses were performed accord-
ing to the manufacturer’s protocols.
2.6. Determination of ALP activity in culture medium
The ability of ALP to hydrolyze P-nitrophenyl phosphate
substrates (Sigma–Aldrich, St. Louis, MO, USA) into the yellow
end-product, p-nitrophenol, was used to quantify the ALP activity
in the culture medium after 2, 8, 14 and 21 days. The absorbance
was measured at 405 nm and the ALP activity was quantiﬁed using
a standard curve based on calf intestinal ALP (Promega, Madison,
WI, USA).
2.7. Staining of DNA and ALP
After 1 and 14 days of culture, scaffolds were cut in half and
ﬁxed in 4% PFA/4.6% D-Mannitol for 15 min and subsequently
stored in 1% PFA/4.6% D-Mannitol until further processing. Attach-
ment and distribution of cells in scaffolds coated with different
concentrations of SIM was evaluated after 1 day of culture by
staining the DNA using DAPI at a concentration of 5 mg/ml. The
ﬂuorescence was assessed using a Nikon Eclipse E-600 ﬂuores-
cence microscope equipped with a Color View III digital camera
controlled by Cell-B software (Olympus, Center Valley, PA).
The presence of ALP positive cells was assessed in scaffolds after
14 days of culture. Fixed scaffolds were submitted to heat induced
epitope retrieval by heating to 95 C in citrate buffer (pH 6) for
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body (Abcam, Cambridge, UK) diluted to 4 lg/ml in 1.25% BSA in
PBS with 0.2% Triton X for overnight at 4 C, followed by incubation
for 30 min at room temperature in goat anti-mouse IgG (Life Tech-
nologies, Paisley, UK) diluted in 2.5% BSA/0.05% Tween-20/PBS at a
concentration of 2 mg/ml. Cell-seeded whole mount stained scaf-
folds were counterstained with DAPI, placed on a coverslip and
covered with Dako ﬂuorescent mounting medium (Dako, Glostrup,
Denmark). Confocal microscopy was performed on a FluoView
1000 (Olympus, Center Valley, PA, USA). Images were analyzed
using Image J (NIH, Bethesda, MD, USA).
2.8. Statistics
The data obtained by cytotoxicity, ALP activity, gene expression
and protein secretion analyses was compared groupwise by using
Holm-Sidak test following a parametric one way ANOVA. When-
ever the equal variance and/or the normality test failed, a
Kruskal–Wallis one way ANOVA on ranks was performed (Sigma
Plot 12.0, Systat Software, San Jose, CA, USA). A probability of
60.05 was considered signiﬁcant.
3. Results and discussion
3.1. Cytocompatibility
The distribution of hAD-MSCs and the cytotoxic effect of SIM
from alginate-coated scaffolds were tested for a wide range of
concentrations (10 lM, 1 lM, 0.1 lM, and 10 nM). The highestFig. 1. Distribution of attached hAD-MSCs after 1 day of culture on alginate-coated scaf
ﬂuorescence microscopy showing nuclei stained with DAPI. The images are representat
10 nM SIM is presented in percentage of control at the same time points. Values represent
p 6 0.05 versus alginate-coated scaffold without SIM.number of evenly distributed hAD-MSCs was observed on scaffolds
with 10 nM SIM (Fig. 1). SIMwas found to be signiﬁcantly cytotoxic
for hAD-MSCs at concentrations above 0.1 lM when cells were
seeded on the scaffolds (data not shown). A prolonged 14-day cyto-
toxicity study of scaffolds with 10 nM SIM did not reveal any cyto-
toxic effects to hAD-MSCs compared to control (Fig. 1). It was
previously shown that concentrations up to 1 lM SIM did not in-
duce cytotoxic response in both human bone marrow-derived
stem cells [24] and hAD-MSCs [12]. The previous results were,
however, obtained using a two-dimensional cell culture system
where the cells were exposed to SIM by overlaid culture medium.
In contrast, in the present study hAD-MSCs were cultured within
porous three-dimensional scaffolds in direct contact with SIM con-
taining alginate.
3.2. Osteogenic effect of SIM coating
The effect of coating TiO2 scaffolds with SIM containing alginate
was investigated in hAD-MSCs by quantiﬁcation of mRNA expres-
sion and protein secretion of osteoblast-related genes.
3.2.1. QRT-PCR analysis
No signiﬁcant differences were observed in the expression of
the transcription factors RUNX2, SOX9 and PPARGmRNA levels after
7, 14 and 21 days of culture (Fig. 2). RUNX2, SOX9 and PPARG are
considered to be the earliest markers of the osteo-, chondro- and
adipogenic lineages [25–27], respectively. Hence, if SIM inﬂuences
the expression of these genes, a change in gene expression may
have taken place before day 7, the earliest time point evaluatedfolds with 1 lM SIM (A), 0.1 lM SIM (B) and 10 nM SIM (C). Cells are visualized by
ive for the respective groups. LDH activity in culture medium from scaffolds with
the mean of three donors (three parallels per donor) +SD (D). Statistical analysis: (a)
Fig. 2. Relative mRNA expression levels for RUNX2, SOX9, PPARG, COL1A1, SPP1, TNFRSF11B, ALPL, VEGFA and BGLAP in hAD-MSCs cultured on scaffolds with 10 nM SIM is
presented in percentage of control, and normalized to reference gene GAPDH at 7, 14 and 21 days. Values represent the mean of three donors (one parallel per donor) +SD.
Statistical analysis: (a) p 6 0.05 versus alginate-coated scaffold without SIM.
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factor that is essential for differentiation of osteoblasts and forma-
tion of bone [28]. Although no signiﬁcant changes were found in
the expression of RUNX2, other markers associated with the
osteogenic differentiation were up-regulated. After 14 days of
culture, the relative expression of COL1A1, marker for preosteo-
blasts or early undifferentiated osteoblast-like cells [29,30], was
signiﬁcantly increased in hAD-MSCs on scaffolds with 10 nM SIM
compared to control (p = 0.029) (Fig. 2). Collagen type 1 synthesis
is known to be a prerequisite for extracellular matrix formation
and mineralization in bone [31]. The ability of collagen type 1 to
further support osteoblast differentiation was demonstrated by
maintenance of the developmental expression of the bone cell phe-
notype in hAD-MSCs. Also the relative expression of SPP1 and ALPL
was signiﬁcantly enhanced in hAD-MSCs on scaffolds with 10 nM
SIM compared to control after 14 days of culture (p = 0.029 and
p = 0.029) (Fig. 2). This also indicates osteogenic differentiation,
as the expression of both ALPL and SPP1 increases when hAD-MSCs
differentiate into mature osteoblasts [32]. After 21 days of culture
the expression levels of COL1A1, SPP1 and ALPL in hAD-MSCs on
scaffolds with 10 nM SIM were all at a level similar to the expres-
sion in the control group. However, the relative expression of
BGLAPwas increasing from day 7 forth and was signiﬁcantly higher
expressed in hAD-MSCs on scaffolds with 10 nM SIM compared to
control (p = 0.002) at day 21 (Fig. 2). The enhanced BGLAP expres-
sion in hAD-MSCs on alginate-coated scaffolds with SIM may
indicate terminal differentiation of osteoblasts [29]. Furthermore,the relative expression of VEGFA was signiﬁcantly enhanced after
7 days of culture in hAD-MSCs on scaffolds with 10 nM SIM com-
pared to control (p = 0.002). It has been shown that elevated VEGFA
expression demonstrates osteogenic differentiation of MSCs [33].
Differentiation and maturation of osteoblasts are characterized
by a temporary up-regulation of COL1A1 and ALPL combined
with a sustained up-regulation of BGLAP [29]. Accordingly,
the gene expression proﬁle indicates osteogenic differentiation of
hAD-MSCs seeded on scaffolds coated with alginate hydrogel
containing 10 nM SIM. These results concur with the previous
report demonstrating up-regulation of osteogenesis-related gene
expression in hAD-MSCs stimulated with SIM [12].
3.2.2. Quantiﬁcation of proteins
Osteogenesis-related proteins were quantiﬁed in the culture
medium to further evaluate the osteogenic response of the
hAD-MSCs. A signiﬁcantly higher amount of OPN was detected in
the medium from hAD-MSCs on scaffolds with 10 nM SIM com-
pared to control at 14 days of culture (p = 0.034) (Fig. 3). OPN is
abundantly secreted by MSCs [34] and is further up-regulated
during the osteogenic differentiation [35]. Also the content of
OPG in the culture medium was signiﬁcantly increased from
hAD-MSCs cultured on scaffolds with 10 nM SIM compared to
control at 8 (p = 0.013) and 21 (p = 0.013) days of culture
(Fig. 3). It has been demonstrated that OPG, known as a potent
anti-osteoclastogenic protein [36], is also capable of priming
undifferentiated human MSCs for enhanced osteogenesis [37]. A
Fig. 3. Secretion of OPN, OPG, VEGFA and OC to culture medium from scaffolds with 10 nM SIM is presented in percentage of control at 2, 4, 8, 14 and 21 days. Values
represent the mean of three donors (one parallel per donor) +SD. Statistical analysis: (a) p 6 0.05 versus alginate-coated scaffold without SIM.
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(p = 0.001), 4 (p = 0.005) and 8 (p = 0.006) days of culture in the
medium from hAD-MSCs on scaffolds with 10 nM SIM compared
to the control group. However, the secretion of VEGFA was contin-
uously increasing in the cultures with 10 nM SIM, and after 14 days
of culture a signiﬁcantly (p = 0.042) higher amount was detected
compared to control (Fig. 3). VEGF signaling is known to play a cen-
tral role in angiogenesis and bone formation [38] and it was re-
cently suggested that VEGFA-mediated control of stem cell fate is
regulated by intracellular VEGFA and not by paracrine mechanisms
[39]. An intracrine mechanism of VEGFA could explain why lower
amount of VEGFA was detected in the medium from scaffolds with
10 nM SIM between day 2 and 8 despite similar mRNA expression
in the two groups. Finally the secretion of OC, a marker of late
osteoblast differentiation [40], was signiﬁcantly enhanced from
hAD-MSCs on scaffolds with 10 nM SIM compared to control at
21 days of culture (p = 0.008) (Fig. 3).Fig. 4. Immunocytochemical staining of ALP in hAD-MSCs cultured on alginate-coated s
(blue) (A). ALP activity in culture medium from scaffolds with 10 nM SIM is presented i
donors (three parallels per donor) +SD. Statistical analysis: (a) p 6 0.05 versus alginate-c
ﬁgure legend, the reader is referred to the web version of this article).Taken together, the osteogenesis-related protein secretion pat-
tern demonstrates the development of the osteoblast phenotype in
hAD-MSCs cultured on scaffolds with 10 nM SIM.
3.2.3. ALP localization and activity
ALP, as a marker of osteogenesis in stem cells [41], was identi-
ﬁed in the cell membrane of hAD-MSCs at day 14 in the majority of
cells, both on scaffolds with 10 nM SIM (Fig. 4) and in the control
group (not shown). The ALP activity in the medium was signiﬁ-
cantly increased from hAD-MSCs cultured on scaffolds with
10 nM SIM compared to control at 8 day of culture (p = 0.002)
(Fig. 4). The peak in ALP activity observed at 8 day of culture
may indicate that the hAD-MSCs have begun osteogenic differenti-
ation. The gene expression of ALPL was only found to be higher in
the SIM cultures compared to the control at day 14. However, ALPL
may have been up-regulated earlier than 7 days, which was the
earliest time point investigated.caffold with 10 nM SIM. ALP is detected in the majority of the cells. ALP (red), DNA
n percentage of control at 2, 8, 14 and 21 days. Values represent the mean of three
oated scaffold without SIM (B). (For interpretation of the references to color in this
144 H. Pullisaar et al. / Biochemical and Biophysical Research Communications 447 (2014) 139–144In summary, the study shows that TiO2 scaffolds coated with
alginate hydrogel containing 10 nM SIM signiﬁcantly enhanced
mRNA expression of COL1A1, ALPL, SPP1, BGLAP and VEGFA without
inducing a cytotoxic response in hAD-MSCs. Furthermore, the
secretion of OPN, OPG, VEGFA and OC was signiﬁcantly increased
from hAD-MSCs cultured on scaffolds with 10 nM SIM, conﬁrming
the osteogenic differentiation. The combination of the local osteo-
genic effect of SIM, hAD-MSCs and the physical properties of TiO2
scaffold may represent a new strategy in stem cell-based bone
tissue engineering.
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